Tumor lysis syndrome as a contributory factor to the development of reversible posterior leukoencephalopathy

• Published in: Neuroradiology 2006-12, Vol.48 (12), p.887-892
• Main Authors: OZKAN, A, HAKYEMEZ, B, OZKALEMKAS, F, ALI, R, OZKOCAMAN, V, OZCELIK, T, TASKAPILIOGLU, O, ALTUNDAL, Y, TUNALI, A
• Format: Article
• Language: English
• Subjects: Antineoplastic Combined Chemotherapy Protocols - adverse effects; Biological and medical sciences; Blindness, Cortical - etiology; Burkitt Lymphoma - drug therapy; Case studies; Chromosome aberrations; Coma - etiology; Encephalitis; Fatal Outcome; Female; Headache - etiology; Headache. Facial pains. Syncopes. Epilepsia. Intracranial hypertension. Brain oedema. Cerebral palsy; Humans; Hypertensive Encephalopathy - etiology; Investigative techniques, diagnostic techniques (general aspects); Magnetic Resonance Imaging; Medical disorders; Medical genetics; Medical sciences; Nervous system; Nervous system (semeiology, syndromes); Neurology; Radiodiagnosis. Nmr imagery. Nmr spectrometry; Radiology; Seizures - etiology; Syndrome; Tumor Lysis Syndrome - complications; Tumors
• ISSN: 0028-3940; 1432-1920
• DOI: 10.1007/s00234-006-0142-8

Reversible posterior leukoencephalopathy syndrome (RPLS) is a recently described clinical and radiological entity comprising headache, seizures, altered level of consciousness and visual disturbances in association with transient posterior cerebral white-matter abnormalities. We report a young woman with Burkitt's lymphoma who developed RPLS after combined chemotherapy administered during the tumor lysis syndrome. The symptoms in this patient fitted well with those of RPLS; they included abrupt alterations in mental status, seizures, headache, visual changes and characteristic neuroradiological findings. She was given further combination chemotherapy without any neurological complications, at which time she had already recovered from both RPLS and tumor lysis syndrome. Although many etiological factors have been reported in the development of RPLS, the underlying mechanism is not yet well understood. With prompt and appropriate management, RPLS is usually reversible, and chemotherapy can be continued after complete recovery from RPLS. We suggest that tumor lysis syndrome should be considered as a contributory factor to the development of RPLS in patients for whom treatment with combined chemotherapy for hematological malignancies is planned.